HomeAI · summaries
Storia in 3 fonti
Natco Pharma shares surge 5% after US FDA's tentative nod Olaparib tablets
Natco Pharma shares rose sharply on Monday after the U.S. FDA granted tentative approval for its generic Olaparib tablets, a bioequivalent version of AstraZenecas Lynparza. The drug addresses a $1.4-billion U.S. market opportunity. The company will manufacture the product, while Alembic Pharmaceuticals will handle its U.S. commercialisation.
Confronto fonti
3 prospettive sulla stessa storiaTimeline cronologica
- ·
economictimes.indiatimes.com
Alembic Pharma partner NATCO gets USFDA tentative nod for generic Olaparib tablets; US market size at USD 1.4 bn
Alembic Pharmaceuticals and NATCO Pharma received tentative USFDA approval for generic Olaparib tablets. This approval is for a cancer drug, which is a generic equivalent of…
- ·
thehindubusinessline.com
Alembic Pharma partner NATCO gets USFDA tentative nod for generic Olaparib tablets; US market size at $1.4 bn
